Predictive factors for poor peripheral blood stem cell mobilization and peak CD34+cell count to guide pre-emptive or immediate rescue mobilization

• Published in: Cytotherapy (Oxford, England) Vol. 14; no. 7; pp. 823 - 829
• Main Authors: Sancho, Juan-Manuel, Morgades, Mireia, Grifols, Joan-Ramon, Juncà, Jordi, Guardia, Ramon, Vives, Susana, Ferrà, Christelle, Batlle, Monsterrat, Ester, Anna, Gallardo, David, Millà, Fuensanta, Feliu, Evarist, Ribera, Josep-Maria
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01.08.2012; Informa Healthcare
• Subjects: Adolescent; Adult; Advanced Basic Science; Aged; Antigens, CD34 - blood; Antigens, CD34 - immunology; Cell Count; Child; Child, Preschool; Female; Flow Cytometry; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation - methods; Hematopoietic Stem Cells - cytology; Hematopoietic Stem Cells - immunology; Humans; lymphoma; Male; Middle Aged; mobilization; multiple myeloma; Multiple Myeloma - therapy; Other; plerixafor; stem cell transplantation; Transplantation, Autologous; multiple myeloma; plerixafor; mobilization; stem cell transplantation; lymphoma
• ISSN: 1465-3249; 1477-2566; 1477-2566
• DOI: 10.3109/14653249.2012.681042

Failure in mobilization of peripheral blood (PB) stem cells is a frequent reason for not performing hematopoietic stem cell transplantation (HSCT). Early identification of poor mobilizers could avoid repeated attempts at mobilization, with the administration of pre-emptive rescue mobilization Data from the first mobilization schedule of 397 patients referred consecutively for autologous HSCT between 2000 and 2010 were collected. Poor mobilization was defined as the collection of < 2×106 CD34+cells/kg body weight (BW). The median age was 53 years (range 4–70) and 228 (57%) were males. Diagnoses were multiple myeloma in 133 cases, non-Hodgkin's lymphoma in 114, acute myeloid leukemia or myelodysplastic syndrome in 81, Hodgkin's lymphoma in 42, solid tumors in 17 and acute lymphoblastic leukemia in 10. The mobilization regimen consisted of recombinant human granulocyte–colony-stimulating factor (G-CSF) in 346 patients (87%) and chemotherapy followed by G-CSF (C + G-CSF) in 51 (13%). Poor mobilization occurred in 105 patients (29%), without differences according to mobilization schedule. Diagnosis, previous therapy with purine analogs and three or more previous chemotherapy lines were predictive factors for poor mobilization. A CD34+cell count in PB > 13.8/μL was enough to ensure ≥ 2×106 CD34+cells/kg, with high sensitivity (90%) and specificity (91%). The prevalence of poor mobilization was high, being associated with disease type, therapy with purine analogs and multiple chemotherapy regimens. The threshold of CD34+ cell count in PB identified poor mobilizers, in whom the administration of immediate or pre-emptive plerixafor could be useful to avoid a second mobilization.